MaaT Pharma SA (EPA:MAAT)

France flag France · Delayed Price · Currency is EUR
4.160
-0.070 (-1.65%)
Sep 4, 2025, 1:39 PM CET
-1.65%
Market Cap68.13M
Revenue (ttm)3.22M
Net Income (ttm)-28.90M
Shares Out16.11M
EPS (ttm)-2.21
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume18,662
Average Volume44,243
Open4.250
Previous Close4.230
Day's Range4.110 - 4.390
52-Week Range4.070 - 9.960
Beta0.01
RSI34.67
Earnings DateSep 16, 2025

About MaaT Pharma

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival in patients with acute myeloid leukemia or blood cancer receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 67
Stock Exchange Euronext Paris
Ticker Symbol MAAT
Full Company Profile

Financial Performance

In 2024, MaaT Pharma's revenue was 3.22 million, an increase of 44.34% compared to the previous year's 2.23 million. Losses were -28.90 million, 46.6% more than in 2023.

Financial Statements

News

There is no news available yet.